Navigation Links
Kinase Inhibitors Market to Reach $11.6 Billion in US, $40.3 Billion Globally by 2016
Date:7/10/2012

FARMINGTON, Conn., July 10, 2012 /PRNewswire-iReach/ -- More companies are investing in kinase inhibitor research to address issues such as resistance, selectivity versus safety, developing lead compounds, and integrating chemistry and biology into development, as well as utilizing the latest technologies and techniques such as fragment- and structure-based design to develop new products. Having accurate market data and analysis is essential to companies that wish to compete on the global stage. With premium market research from the world's leading publishers, Global Information Inc. helps businesses stay on the cutting edge with the best forecasts, research, and analyses.

(Photo: http://photos.prnewswire.com/prnh/20120710/CG37789)

Global Information is pleased to announce the immediate availability of three significant new reports on Kinase Inhibitors.

Kinase Inhibitors: Global Markets -- Focus on Europe

Kinase Inhibitors: Global Markets -- Focus on US

Kinase Inhibitors: Global Markets -- Focus on Emerging Markets

The overall goal of this series is to provide a comprehensive understanding of the current and future characteristics for kinase inhibitors, which include tyrosine inhibitors, multi-target kinase inhibitors, serine/threonine inhibitors and monoclonal antibody kinase inhibitors.

Each report offers market sizes with sales and revenues figures from 2011 to 2016 for kinase inhibitors in the pharmaceutical and biotechnology industry. Market projections, market shares and a technology SWOT analysis are also included.

Global revenues for kinase inhibitors were nearly $29.1 billion in 2011 and are projected to reach nearly $40.3 billion in 2015 at a five-year compound annual growth rate (CAGR) of 6.7%. The kinase inhibitors market is witnessing an increasing number of novel kinase inhibitors being utilized in human trials, particularly in the development of next-generation inhibitors that target cancers and other disease, including inflammation.

The United States kinase inhibitor market accounted for $10.4 billion in 2011 and is expected to reach $11.6 billion by 2016 at a CAGR of 2.2%. Monoclonal antibody kinase inhibitors in the U.S. market brought in $7.6 billion in 2010 and came down to $6.6 billion in 2011. This segment is expected to continue on a downward trend at a CAGR of -4% to reach $5.4 billion in 2016.

Strong growth is expected in the emerging markets segment for kinase inhibitors, which reached $2.9 billion in 2010 and $4.1 billion in 2011 and is expected to post $8.4 billion by 2016 at a CAGR of 15.2%. Antibody kinase inhibitors in the emerging markets segment is expected to reach $4.3 billion by 2016.

An Executive Summary of this analysis and a free sample of each report is available from Global Information, Inc:

Emerging Markets
http://www.giiresearch.com/report/bc246348-kinase-inhibitors-global-markets-focus-on-emerging.html

US Markets
http://www.giiresearch.com/report/bc246349-kinase-inhibitors-global-markets-focus-on-us.html

European Markets
http://www.giiresearch.com/report/bc246350-kinase-inhibitors-global-markets-focus-on-europe.html

BCC Research provides a multitude of studies on the Biotechnology markets. Topics range from stem cells to enzyme inhibitors and drug discovery technologies. Each report analyzes the market along with its applications, regulatory environment, technology, market projections and market share. Discover more at http://www.giiresearch.com/publisher/BC/biotechnology.shtml

About Global Information Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.

Media Contact: Jeremy Palaia Global Information, Inc., 1-860-674-8796, Press@gii.co.jp  

News distributed by PR Newswire iReach: https://ireach.prnewswire.com



'/>"/>
SOURCE Global Information, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
2. Global Angiogenesis Inhibitors and Stimulators Industry
3. Global Markets for Enzyme Inhibitors
4. Emerging Markets for Enzyme Inhibitors Surge, To Grow More Than 50% by 2016
5. United States Market for Psoriatic Arthritis Pharmacotherapy
6. Neurostimulation Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
7. Analysis of the North American Radiology Image and Information Management Systems Market
8. Sports Medicine Implants Market - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
9. North America ENT Devices Market Outlook to 2018 - Diagnostic Devices, Hearing Aid Devices, Hearing Implants and Others
10. Middle East and Africa Surgical Equipment Market Outlook to 2018 -Electrosurgical Devices, Hand Instruments and Surgical Sutures
11. Medical Diagnostic & Therapeutic Ultrasound Devices Market (2012 - 2017) - Global Trends & Competitive Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)...  Wellbridge Health and Gateway Health proudly announce a dynamic ... and Medicaid plan members with specific high risk needs. ... of this group of consumers, Wellbridge combines technology and population ... insight into members, daily behaviors and lifestyle. ... , , ...
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, 2016 ... today announced preliminary safety and efficacy data from ... oral selective MDM2 inhibitor, suggesting that DS-3032 may ... relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic ... part of the phase 1 study of DS-3032 were ...
(Date:12/5/2016)... 2016 Eisai Inc. announced today new analyses ... Meeting of the American Epilepsy Society (AES). ... an adjunctive therapy for the treatment of partial onset ... primary generalized tonic-clonic seizures (PGTC) in patients with epilepsy ... see Important Safety Information for FYCOMPA, including Boxed WARNING ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... ... that the company will provide alerting technology to Central Illinois Health Information ... $1.7 million in federal funds as the sole sub-recipient participating with the ...
(Date:12/5/2016)... , ... December 05, 2016 , ... Dr. Barry M. ... Cosmetic Plastic Surgery, who recently participated in the 36th Annual Cutting Edge Aesthetic Symposium ... the newest techniques for getting that perfect, yet natural-looking, nose. Dr. Weintraub, who is ...
(Date:12/5/2016)... ... December 05, 2016 , ... Florida Hospital has named Robin ... Region. McGuinness brings experience in executive leadership and clinical practice, as well as ... In her new role, that officially begins December 12, 2016, she will set ...
(Date:12/5/2016)... Franklin Lakes, NJ (PRWEB) , ... December 05, ... ... the recording studio teaming up on new songs with prolific Songwriter-Producer Corey “Chorus” ... Jamie Foxx, Kelly Rowland, Ciara, Brandy…just to name a few.     https://twitter.com/coreychorus ...
(Date:12/5/2016)... ... December 05, 2016 , ... The new knee compression sleeves come ... buy neoprene knee sleeves for lifting and any sport that requires knee ... two main aspects to provide a higher quality knee sleeve performance. Firstly it is ...
Breaking Medicine News(10 mins):